SequelSEC

Cullinan Therapeutics, Inc. CGEM

Biological Products, (No Diagnostic Substances) · CIK 0001789972 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2022-12-31
Operating income
$144.65M
Fiscal year ended 2022-12-31
Free cash flow
-$127.80M
Fiscal year ended 2022-12-31

Cullinan Therapeutics, Inc. (CGEM) reported revenue of $0 and net income of $111.21M for the fiscal year ended 2022-12-31. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Cullinan Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Cullinan Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2022-12-31
Revenue$0
Cost of revenueUnavailable
Gross profitUnavailable
Operating income$144.65M
Net income$111.21M
Research & development$91.95M
Weighted-average diluted sharesUnavailable
Pretax income$151.32M
Income tax expense$42.12M
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$40.19M
Selling & marketingUnavailable

Balance

Cullinan Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2022-12-31
Cash & equivalents$156.15M
Total assets$561.12M
Current assets$474.47M
Total liabilities$26.09M
Current liabilities$22.50M
Total equity incl. NCI$535.03M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$2.66M

Cash flow

Cullinan Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2022-12-31
Operating cash flow-$126.66M
Capital expenditures$1.13M
Investing cash flow$248.98M
Financing cash flow-$25.93M
Net change in cashUnavailable
Stock-based compensation$27.96M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$93.00K

Derived

Cullinan Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2022-12-31
Free cash flow-$127.80M
Gross marginUnavailable
Operating marginUnavailable
FCF marginUnavailable
SBC / revenueUnavailable
Current ratio21.09x
Revenue YoY growth-100.0%
Net marginUnavailable
R&D / revenueUnavailable
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rate27.8%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open CGEM in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-03-10View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.